Pooled data from 2 phase 3 studies.
Much needed identification of factors associated with persistent AD.
Findings from a meta-analysis of observational Studies.
Better-tolerated approach similarly effective vs conventional PDT for grade I-II lesions.
A promising new treatment option warrants further study.
Patient-reported benefits vs saline not corroborated by physician photo review.
In 33 countries, malignant melanoma mortality rates were greater in males than females across the 30-year observation period.
Data underscore the importance of vaccination.
Effect is limited to nonmelanoma skin cancer.
Increased awareness and early recognition may reduce treatment interruptions.
Approval is for 7 rheumatologic, gastrointestinal, or dermatologic indications.
Extrapolation suggests 16.5 million adults are affected.
Analysis did not include newer agents such as secukinumab and ixekizumab.
A promising treatment option.
A study of hospitalized patients.
Study shows relative benefits for each treatment option.
Results from a meta-analysis.
